GLP1R and Obesity: The important finding that the present analysis highlighted is that the efficacy of GLP‐1 agonists in secondary prevention of adverse cardiovascular outcomes in patients with underlying overweight/obesity but no diabetes is generally similar and even has a greater magnitude of effect compared to CVOTs of patients with diabetes and established cardiovascular conditions (RR = 0.81 vs. 0.88).